Phenolic acid salts of gabapentin in solid dosage forms and methods of use
View Patent ↗The present invention relates to pharmaceutical compositions of gabapentin tannate in solid dosage form, processes for production of those compositions and methods of use of those compositions. Tannate salts of active pharmaceutical ingredients are used in sustained release applications and to improve certain organoleptic properties such as taste. The process may utilize either natural or synthetic tannic acid.
1. A process for preparing a gabapentin tannate pharmaceutical composition, comprising: reacting gabapentin with tannic acid to produce a pharmaceutically effective amount of gabapentin tannate in solid dosage form wherein the tannic acid component is of either natural or synthetic origin.
2. The process of claim 1 including selecting either natural or synthetic tannic acid.
3. The process of claim 1 including providing one or more pharmaceutically acceptable excipients.
4. A process for preparing a gabapentin tannate pharmaceutical composition, comprising:
mixing an anti-clumping agent and tannic acid together to form a reaction mixture;
adding gabapentin to said reaction mixture; and
adding one or more solvents to said reaction mixture.
5. The process of claim 4 , including selecting said solvent from a group consisting of water, purified water, isopropyl alcohol, ethanol, glycerin, propylene glycol, mineral oil and mixtures thereof.
6. A process for preparing a gabapentin tannate pharmaceutical composition, comprising:
mixing one or more anti-clumping agents, tannic acid and gabapentin together either in the presence of one or more solvents or at a suitable temperature so as to produce a pharmaceutically effective amount of gabapentin tannate.
7. The process of claim 6 , including selecting said solvents from a group consisting of water, purified water, ethanol, isopropyl alcohol, glycerin, propylene glycol, mineral oil and mixtures thereof.
8. The process of claim 6 , including providing said tannic acid at a weight W 1 and gabapentin at a weight W 2 wherein W 1 is from about 0.05 to about 20 times W 2 .
9. The process of claim 8 , including selecting said one or more anti-clumping agents from a group consisting of magnesium aluminum silicate, xanthan gum, polyvinylpyrrolidone, cellulose compounds, magnesium stearate, colloidal silica, talc, stearic acid, calcium stearate, lactose, mannitol, sucrose and mixtures thereof.
10. The process of claim 9 , including providing said one or more anti-clumping agents at a concentration of from about 0.01 to about 95% by weight of said composition.